512 related articles for article (PubMed ID: 19417585)
1. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
3. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors.
Sung CO; Ahn G; Song SY; Choi YL; Bae DS
Int J Gynecol Pathol; 2009 Nov; 28(6):529-34. PubMed ID: 19851199
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
5. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.
Dall'Asta A; Gizzo S; Musarò A; Quaranta M; Noventa M; Migliavacca C; Sozzi G; Monica M; Mautone D; Berretta R
Int J Clin Exp Pathol; 2014; 7(11):8136-42. PubMed ID: 25550862
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
8. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
Deng ZJ; Guo LN
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
[No Abstract] [Full Text] [Related]
9. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
[TBL] [Abstract][Full Text] [Related]
10. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
Ip PP; Tse KY; Tam KF
Adv Anat Pathol; 2010 Mar; 17(2):91-112. PubMed ID: 20179432
[TBL] [Abstract][Full Text] [Related]
11. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
12. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
13. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
14. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: a morphological study of these grey zones with clinical correlation.
Deodhar KK; Goyal P; Rekhi B; Menon S; Maheshwari A; Kerkar R; Tongaonkar HB
Indian J Pathol Microbiol; 2011; 54(4):706-11. PubMed ID: 22234095
[TBL] [Abstract][Full Text] [Related]
15. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP).
Travaglino A; Raffone A; Gencarelli A; Neola D; Oliviero DA; Alfano R; Campanino MR; Cariati F; Zullo F; Mollo A; Insabato L
Pathol Res Pract; 2021 Oct; 226():153592. PubMed ID: 34481212
[TBL] [Abstract][Full Text] [Related]
16. Atypical uterine leiomyoma: a case report and review of the literature.
Manxhuka-Kerliu S; Kerliu-Saliu I; Sahatciu-Meka V; Kerliu L; Shahini L
J Med Case Rep; 2016 Jan; 10():22. PubMed ID: 26801982
[TBL] [Abstract][Full Text] [Related]
17. [Smooth muscle tumor of uncertain malignant potential (STUMP)--clinico-pathomorphological analysis of the cases and literature review].
Dańska-Bidzińska A; Bakuła-Zalewska E; Nasierowska-Guttmejer A; Kowalewska M; Barnaś E; Sobiczewski P; Bidziński M
Ginekol Pol; 2012 Jun; 83(6):412-6. PubMed ID: 22880459
[TBL] [Abstract][Full Text] [Related]
18. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
Patil DT; Laskin WB; Fetsch JF; Miettinen M
Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
20. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
